Search

It has been more than 3 months now since the first case of COVID-19 was reported in Turkey. Globally, the number of confirmed cases and deaths reached 9,653,048 and 491,128 respectively, as reported by 216 countries by June 27, 2020. Turkey had 1,396 new cases, 194,511 total cases, and 5,065 deaths by the same date. From the first case until today, the Turkish Thoracic Society (TTS) has been very proactive in educating doctors, increasing public awareness, undertaking academic studies, and assisting with public health policies. In the present report, social, academic, and management perspectives of the pandemic are presented under appropriate subtitles. During this critical public health crisis, TTS has once again demonstrated its readiness and constructive stance by supporting public health, healthcare workers, and the environment. This review summarizes the perspective of TTS on each aspect of the COVID-19 pandemic and casts light on its contributions. C1 [Kokturk, Nurdan] Gazi Univ, Sch Med, Dept Pulm Med, Ankara, Turkey. [Itil, Bahriye Oya; Ergan, Begum; Kilinc, Oguz; Simsek, Gokcen Omeroglu; Ucan, Eyup Sabri] Dokuz Eylul Univ, Sch Med, Dept Pulm Med, Izmir, Turkey. [Altinisik, Goksel] Pamukkale Univ, Sch Med, Dept Pulm Med, Denizli, Turkey. [Adiguzel, Nalan; Karkurt, Zuhal] Univ Hlth Sci, Istanbul Sureyyapas Chest Dis Training & Res Hosp, Dept Intens Care Unit Pulm Med, Istanbul, Turkey. [Akgun, Metin] Ataturk Univ, Dept Pulm Med, Sch Med, Erzurum, Turkey. [Akyildiz, Levent] Mem Dicle Hosp, Clin Pulm Med, Diyarbakir, Turkey. [Altin, Sedat; Akyil, Fatma Tokgoz] Univ Hlth Sci, Yedikule Chest Dis & Chest Surg Training & Res Ho, Dept Pulm Med, Istanbul, Turkey. [Arikan, Huseyin] Yuzuncu Yil Univ, Dursun Odaba Med Ctr, Med Intens Care Unit, Van, Turkey. [Ates, Gungor] Sultan Hosp, Dept Pulm Med, Diyarbakir, Turkey. [Ay, Pinar] Marmara Univ, Sch Med, Dept Publ Hlth, Istanbul, Turkey. [Aykac, Nilufer] Gayrettepe Florence Nightingale Hosp, Clin Pulm Med, Istanbul, Turkey. [Babayigit, Cenk] Mustafa Kemal Univ, Sch Med, Dept Pulm Med, Antakya, Turkey. [Bostan, Pinar] Istanbul Bilgi Univ, Sch Hlth Sci, Istanbul, Turkey. [Cinel, Guzin] Ankara Yildirim Beyazit Univ, Sch Med Ankara, Dept Pediat Pulmonol, Ankara, Turkey. [Calisir, Haluk Celaleddin] Yapi Kredi Hlth & Retirement Fdn, Istanbul, Turkey. [Celik, Pinar; Gultekin, Okkes; Havlucu, Yavuz; Yorgancioglu, A. Arzu] Celal Bayar Univ, Sch Med, Dept Pulm Med, Manisa, Turkey. [Cetinkaya, Pelin Duru] Univ Hlth Sci, Adana City Training & Res Hosp, Dept Pulm Med, Adana, Turkey. [Dagli, Elif] Turkish Thorac Soc, Ankara, Turkey. [Demir, Ahmet Ugur] Hacettepe Univ, Sch Med, Dept Pulm Med, Ankara, Turkey. [Demir, Canan; Sandal, Abdulsamet] Occupat & Environm Dis Hosp, Clin Occupat Dis, Ankara, Turkey. [Dikensoy, Oner] Acibadem Univ, Sch Med, Dept Pulm Med, Istanbul, Turkey. [Edis, Ebru Cakir] Trakya Univ, Sch Med, Dept Pulm Med, Edirne, Turkey. [Elbek, Osman] Kadikoy Florence Nightingale Hosp, Clin Pulm Med, Istanbul, Turkey. [Erdinc, Munevver; Goksel, Tuncay; Gurgun, Alev; Basoglu, Ozen K.; Sayiner, Abdullah] Ege Univ, Sch Med, Dept Pulm Med, Izmir, Turkey. [Eyuboglu, A. Fusun Oner] Baskent Univ, Sch Med, Dept Pulm Med, Ankara, Turkey. [Gemicioglu, Bilun] Istanbul Univ Cerrahpasa, Cerrahpasa Sch Med, Dept Pulm Dis, Istanbul, Turkey. [Gulhan, Erkmen] Ataturk Chest Dis & Thorac Surg Training & Res Ho, Dept Thorac Surg, Ankara, Turkey. [Gurkan, Canan Gunduz; Yildiz, Tekin] Univ Hlth Sci, Sureyyapasa Chest Dis & Thorac Surg Training & Re, Dept Pulm Med, Istanbul, Turkey. [Karakurt, Sait] Marmara Univ, Sch Med, Dept Intens Care Unit Pulm Med, Istanbul, Turkey. [Kocabas, Ali] Cukurova Univ, Sch Med, Dept Pulm Med, Adana, Turkey. [Kul, Seval] Gaziantep Univ, Sch Med, Dept Biostat, Gaziantep, Turkey. [Nayci, Sibel] Mersin Univ, Sch Med, Dept Pulm Med, Mersin, Turkey. [Ozkan, Metin] Ankara Mem Hosp, Clin Pulm Med, Ankara, Turkey. [Pinarer, Ozgun] Galatasaray Univ, Sch Engn, Istanbul, Turkey. [Salturk, Cuneyt] Istanbul Yeni Yuzyil Univ, Sch Med, Dept Pulm Med, Istanbul, Turkey. [Sen, Elif] Ankara Univ, Sch Med, Dept Pulm Med, Ankara, Turkey. [Karadag, Bulent Taner] Marmara Univ, Sch Med, Dept Pediat Pulmonol, Istanbul, Turkey. [Toreyin, Zehra Nur] Hlth Sci Univ, Adana City Training & Res Hosp, Dept Occupat Dis, Ankara, Turkey. [Varol, Ayhan] Kepez State Hosp, Clin Pulm Med, Antalya, Turkey. [Yasin, Yesim] Acibadem Univ, Sch Med, Dept Publ Hlth, Istanbul, Turkey. [Bayram, Hasan] Koc Univ, Sch Med, Dept Pulm Med, Istanbul, Turkey.

PubMed ID: 29631525, Introduction: Colistimethate sodium (CMS) is frequently used in the treatment of nosocomial multidrug-resistant gram-negative infections. Nephrotoxicity is the most important side effect. The aim of this study is to evaluate the effect of colistin on nephrotoxicity and to assess prognosis in patients treated with CMS due to hospital-acquired pneumonia (HAP). Materials and Methods: Patients treated with CMS for HAP due to multidrug-resistant Pseudomonas aeruginosa or Acinetobacter baumannii were included in this cohort study. Results: We evaluated 281 patients treated with two different brands of CMS whose administration dose is different: imported (n= 58, low dose/kg) and domestic (n= 223, high dose/kg). Nephrotoxicity developed in 175 patients (62.3%). The median age (73 vs. 66 years, p= 0.004) and mortality rates were higher (66.9% vs. 52.8%, p= 0.022) in patients having nephrotoxicity. The patients receiving high dose/kg had higher nephrotoxicity rate (67.7% vs. 41.4%, p< 0.001). The clinical, bacteriological response and mortality rates of the whole group were 52.0%, 61.0%, 61.6%, respectively. The clinical and bacteriological response rates were similar in the different dose groups. Multivariate analysis showed that nephrotoxicity was associated with domestic brand depending on use of high dose (OR= 3.97), advanced age (ß= 0.29, p= 0.008), male gender (OR= 2.60), hypertension (OR= 2.50), red blood cells transfusion (OR= 2.54), absence of acute kidney injury (OR= 10.19), risk stage of RIFLE (OR= 11.9). Conclusion: Nephrotoxicity is associated with the use of high dose colistin, age, gender, hypertension, red blood cells replacement and RIFLE stage. The mortality rate is higher in patients developing nephrotoxicity. © 2018, Ankara University. All rights reserved.